Invivyd Inc.

Company Overview

Business Model: INVIVYD, INC. is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. The company's initial focus is on SARS-CoV-2, the virus that causes COVID-19, with plans to expand into other high-need indications such as respiratory syncytial virus (RSV) and measles. Their strategy involves leveraging a bespoke platform for continuous pharmaceutical activity against viral evolution, supported by internal research and collaborations.

Market Position: INVIVYD, INC. has received regulatory authorization for only one product, PEMGARDA® (pemivibart), for pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals in the U.S. As of the filing date, no other mAb has been approved in the U.S. for prevention or treatment of COVID-19, positioning PEMGARDA as a unique offering for this vulnerable population. The company estimates a market of over 9 million immunocompromised people in the U.S. who may not adequately respond to COVID-19 vaccination. The company faces competition from vaccines, antiviral agents, and other therapeutics for COVID-19, as well as from companies developing therapies for RSV and measles.

Recent Strategic Developments:

• PEMGARDA Emergency Use Authorization (EUA): Received EUA from the U.S. Food and Drug Administration (FDA) on March 22, 2024, for PEMGARDA injection for intravenous (IV) use, for pre-exposure prophylaxis of COVID-19 in adults and adolescents (12 years and older, weighing at least 40 kg) with moderate-to-severe immune compromise.
• VYD2311 Development: Nominated VYD2311 as a next-generation mAb candidate for COVID-19 in January 2024. Positive full Phase 1/2 clinical data for VYD2311 (safety and pharmacokinetics) announced in June 2025.
• REVOLUTION Clinical Program: In August 2025, announced alignment with FDA on a rapid pathway to potential Biologics License Application (BLA) approval for VYD2311 for COVID-19 prevention. FDA cleared Investigational New Drug (IND) application for VYD2311 in October 2025. Initiated DECLARATION, a Phase 3 randomized, triple-blind, placebo-controlled clinical trial for VYD2311 safety and efficacy (single or monthly IM doses) in December 2025, with top-line data anticipated mid-2026. Aligned with FDA on LIBERTY, a Phase 3 randomized, double-blind clinical trial for VYD2311 safety, serum virus neutralizing antibody responses, and pharmacokinetics (VYD2311, mRNA COVID vaccine, co-administered) in February 2026.
• Fast Track Designation: FDA granted "Fast Track" designation for VYD2311 for the prevention of COVID-19 in individuals with underlying risk factors for progression to severe disease.
• SPEAR Study Group: Formed in July 2025 with investigators to guide clinical trials evaluating anti-SARS-CoV-2 spike protein mAb therapy for Long COVID or Post-Vaccination Syndrome (PVS) using next-generation antibodies like VYD2311.
• Pipeline Expansion: Selected VBY329, a potential best-in-class mAb candidate for prevention of RSV infections in neonates, infants, and children, in November 2025, with IND readiness expected in H2 2026. Targeting identification of a preclinical mAb candidate for measles treatment and prevention in H1 2026.
• Variant Monitoring: Ongoing active SARS-CoV-2 variant monitoring, with PEMGARDA and VYD2311 demonstrating continued neutralizing activity against dominant variants such as JN.1, KP.3.1.1, XEC, LP.8.1, and XFG throughout 2024 and 2025.

Geographic Footprint: The company's primary operational regions are the U.S. for commercialization and clinical development. Clinical trials for VYD2311 have been conducted in Australia. The company operates as a hybrid company with employees in New Haven, Connecticut (corporate headquarters), Newton, Massachusetts (laboratory), and remotely across various U.S. states.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 93.0% (Calculated as (53.4 - 3.7) / 53.4)
• Operating Margin: -104.1% (Calculated as -55.6 / 53.4)
• Net Margin: -98.3% (Calculated as -52.5 / 53.4)

Investment in Growth:

• R&D Expenditure: $38.3 million (71.7% of revenue)
• Capital Expenditures: $0.2 million
• Strategic Investments:
  • Adimab Assignment Agreement milestone payments: $11.1 million paid through December 31, 2025.
  • Adimab Collaboration Agreement quarterly fees: $2.4 million recognized in 2025.
  • Adimab Platform Transfer Agreement annual fees: $2.0 million recognized in 2025.

Business Segment Analysis

The company manages its operations as a single reportable and operating segment for the purposes of assessing performance and making operating decisions. The company's chief operating decision maker reviews the company's financial information on an aggregated basis.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed in the filing for the period.
• Dividend Payments: The company has never declared or paid any cash dividends on its capital stock and currently intends to retain all available funds and future earnings for business development and growth.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: Not disclosed in the filing.

Balance Sheet Position:

• Cash and Equivalents: $226.7 million (as of December 31, 2025)
• Total Debt: $0 (as of December 31, 2025, no amounts drawn under Term Facility)
• Net Cash Position: $226.7 million
• Credit Rating: Not disclosed in the filing.
• Debt Maturity Profile: The company entered into a Loan and Security Agreement in April 2025 for a senior secured term loan facility of up to $30 million (Term Facility). Loans under the Term Facility are due and payable on March 1, 2029. Principal repayments are scheduled in 24 consecutive equal monthly installments starting April 1, 2027 (extendable to April 1, 2028 upon certain net product revenue milestones). As of December 31, 2025, no amounts had been drawn down due to unfulfilled financial covenants and conditions.

Cash Flow Generation:

• Operating Cash Flow: ($58.1 million) (used in operating activities for the year ended December 31, 2025)
• Free Cash Flow: ($58.3 million) (Calculated as Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: The company does not own or operate manufacturing facilities. It relies on contract development and manufacturing organizations (CDMOs) for the development and manufacture of its mAb candidates. PEMGARDA and VYD2311 are produced using industry-standard mAb manufacturing processes, including recombinant Chinese Hamster Ovary commercial cell lines, fed-batch suspension cell culture, and chromatography column-based purification. WuXi Biologics uses an industry-standard sterile liquid drug product manufacturing process.

Supply Chain Architecture: Key Suppliers & Partners:

• CDMO: WuXi Biologics (Hong Kong) Limited - Sole contract manufacturing partner for COVID-19 product candidates (PEMGARDA and VYD2311), responsible for CMC development, clinical, and commercial drug substance and drug product supply. Also procures raw materials, including single-source purification resins and cell culture media.
• Antibody Discovery/Engineering: Adimab, LLC - Provides antibody discovery, engineering, and optimization services. Exclusive access to Adimab’s B-cell mining, protein and antibody engineering capabilities for coronavirus antibody discovery. Also granted rights to practice certain elements of Adimab’s platform technology for antibody discovery, engineering, and optimization.
• Clinical Research: Contract Research Organizations (CROs) and other third parties - Engaged to conduct discovery, nonclinical, preclinical, clinical, and commercial activities, including monitoring and managing data.

Facility Network:

• Manufacturing: Relies exclusively on WuXi Biologics' China-based facilities for clinical and commercial supply of COVID-19 mAbs.
• Research & Development: Leases dedicated laboratory and office space in Newton, Massachusetts.
• Distribution: Utilizes a third-party logistics distribution agent for product storage and distribution to end customers (specialty distributors, infusion centers, healthcare providers, and provider institutions in the U.S.).
• Corporate Headquarters: Leases office space in New Haven, Connecticut for general and administrative purposes. Entered into an agreement in January 2026 to lease approximately 33,000 square feet of new office space in New Haven, Connecticut, with an initial term of 129 months.

Operational Metrics: Not explicitly detailed in the filing beyond financial performance.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Directly hired key leaders for sales, marketing, market access, and medical affairs teams, and established a field sales force to support PEMGARDA commercialization.
• Channel Partners: Primarily sells PEMGARDA to third-party specialty distributors in the U.S. Also sells directly to a small number of infusion centers, healthcare providers, and provider institutions.
• Digital Platforms: Not explicitly detailed in the filing.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Three specialty distributors accounted for 46%, 23%, and 17% of total gross sales for the year ended December 31, 2025.
• Customer Concentration: Significant revenue concentration with a few specialty distributors.

Geographic Revenue Distribution:

• United States: 100% of total product revenue for the years ended December 31, 2025 and 2024.
• Growth Markets: Not explicitly detailed in the filing.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industry is characterized by rapid technological evolution, intense competition, and a strong emphasis on intellectual property. The COVID-19 market is dynamic, with evolving SARS-CoV-2 variants impacting mAb effectiveness and a need for continuous innovation. The market for prevention and treatment of COVID-19 is evolving, with increasing demand for options for immunocompromised individuals.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• AstraZeneca plc and Roche Pharmaceuticals: Companies with active COVID-19 antibody-based programs.
• Merck and Co., Inc. (oral), Pfizer Pharmaceuticals (oral), and Gilead (IV): Companies with approved or authorized antiviral programs for the treatment of COVID-19.
• Moderna, Pfizer-BioNTech, Novavax: mRNA and protein subunit vaccine manufacturers for COVID-19 prevention.
• AstraZeneca and Sanofi (Beyfortus® (nirsevimab)), Merck (Enflonsia™ (clesrovimab)): mAbs for RSV prevention.
• Merck and GSK: MMR (Measles, Mumps, Rubella) vaccine manufacturers for measles prevention.

Emerging Competitive Threats: New SARS-CoV-2 variants that reduce the activity of existing mAbs, more efficacious prophylaxis or treatments for COVID-19 from competitors, and disruptive technologies such as AI that could accelerate competitor discovery and development.

Competitive Response Strategy: The company's strategy is to continuously discover and engineer new mAb candidates that can respond to emerging virus variants or improve upon current antibodies' biophysical properties and clinical profiles. This includes leveraging its integrated technology platform, ongoing variant surveillance, and seeking streamlined development pathways with regulators.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Newly emerging and future SARS-CoV-2 variants could reduce the activity and effectiveness of mAbs, significantly affecting clinical trials, regulatory authorization, and commercialization. The market for COVID-19 therapeutics is subject to evolving dynamics, including greater seasonality of demand as COVID-19 becomes endemic.
• Technology Disruption: Risk that new SARS-CoV-2 variants are less susceptible to current mAb modifications, or that preclinical results are not replicated in clinical trials. Competitors may more effectively utilize new technologies, including AI, to discover, develop, and commercialize competing products.
• Customer Concentration: Significant portion of gross sales (46%, 23%, and 17% in 2025) are from three specialty distributors, posing concentration risk.

Operational & Execution Risks

• Supply Chain Vulnerabilities:
  • Supplier Dependency: Reliance on a single contract manufacturer, WuXi Biologics, for COVID-19 product candidates, and a limited number of vendors for specialty materials and equipment. Loss of these suppliers or their inability to provide sufficient quantities or quality could cause delays.
  • Geographic Concentration: Exclusive reliance on WuXi Biologics' China-based facilities for clinical and commercial supply, exposing the company to trade restrictions, sanctions, and changes in foreign regulatory requirements (e.g., BIOSECURE Act).
  • Capacity Constraints: Manufacturing mAbs is complex and time-consuming; production difficulties, lack of desired manufacturing capacity, or raw material shortages could delay development and commercialization.
• Capacity Constraints: Manufacturing mAbs is complex and time-consuming; production difficulties, lack of desired manufacturing capacity, or raw material shortages could delay development and commercialization.
• Clinical Trial Delays: Preclinical studies and clinical trials are expensive, time-consuming, and uncertain. Delays can arise from patient enrollment/retention issues, regulatory disagreements on trial design, unexpected adverse events, or changes in SARS-CoV-2 variants impacting efficacy.
• Manufacturing Quality: Risk of contamination, technical issues, or non-compliance with cGMP requirements by the company or its CDMOs, leading to delays, interruptions, or regulatory enforcement actions.

Financial & Regulatory Risks

• Market & Financial Risks:
  • Going Concern: The company's financial condition raises substantial doubt about its ability to continue as a going concern, with existing cash and cash equivalents not sufficient to fund operations beyond one year from the issuance of the financial statements.
  • Funding Needs: Requires additional funding through revenues, equity offerings, grants, debt, or collaborations. Inability to secure funding could force curtailment of operations.
  • Indebtedness: Loan Agreement with Silicon Valley Bank for up to $30 million Term Facility, secured by substantially all assets (excluding IP). Failure to meet financial covenants or conditions could result in default and acceleration of obligations.
• Regulatory & Compliance Risks:
  • EUA Termination: PEMGARDA's EUA could be terminated or revoked by the FDA if emergency use is no longer warranted or if safety/efficacy concerns arise (e.g., reduced neutralizing activity against new variants), requiring pursuit of traditional, lengthy, and unpredictable regulatory approval.
  • Regulatory Approval Uncertainty: No assurance of obtaining full regulatory approval for PEMGARDA or any other product candidates (e.g., VYD2311 BLA).
  • Off-label Use: Risk of off-label use or misuse of products, potentially harming reputation, leading to product liability suits, or regulatory penalties.
  • Healthcare Reform: U.S. and foreign healthcare legislative and regulatory reforms (e.g., ACA, IRA, OBBBA) could negatively impact business by affecting coverage, pricing, and reimbursement.
  • Data Privacy: Subject to evolving federal, state, and foreign data privacy and security laws (e.g., HIPAA, GDPR, CCPA), with non-compliance leading to investigations, fines, litigation, and reputational harm.
  • AI Regulation: Global trend towards more regulation of AI technologies, which could increase compliance costs.

Geopolitical & External Risks

• Geopolitical Exposure: Unfavorable global economic conditions and geopolitical events (e.g., trade tensions between U.S. and China, military conflicts) could adversely affect business, clinical trials, and manufacturing activities, particularly due to reliance on foreign CDMOs.
• Trade Relations: Increased trade restrictions, tariffs, or taxes on imports from countries where products are manufactured (e.g., China) could disrupt supply or increase costs.
• Sanctions & Export Controls: Foreign CDMOs may become subject to U.S. legislation (e.g., BIOSECURE Act), investigations, sanctions, or trade restrictions, potentially impacting supply and U.S. government contracting opportunities.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Monoclonal Antibody (mAb) Therapies: Focus on discovery, development, and commercialization of mAbs for serious viral infectious diseases.
• Bespoke Platform: Designed to deliver new product candidates with continuous pharmaceutical activity in the face of viral evolution, enabling rapid updates.
• Viral Surveillance: Continuous monitoring and predictive modeling for SARS-CoV-2 variants, identifying dominant spike glycoprotein sites and common mutational escape routes.
• Antibody Engineering: Leveraging internal expertise and Adimab's capabilities to improve potency, breadth, biophysical properties, and developability of mAb candidates, including half-life extension and Fc region modifications.
• Pipeline Expansion: Expanding beyond COVID-19 to RSV (VBY329) and measles.

Innovation Pipeline:

• VYD2311: Next-generation mAb candidate for COVID-19, in Phase 3 clinical development (DECLARATION and LIBERTY trials) for prevention, with top-line data anticipated mid-2026.
• VBY329: Potential best-in-class mAb candidate for prevention of RSV infections in neonates, infants, and children, expected to advance toward IND readiness in H2 2026.
• Measles mAb: Targeting identification of a preclinical mAb candidate for treatment and prevention in H1 2026.
• Anti-SARS-CoV-2 mAbs: Additional candidates in discovery and preclinical characterization.

Intellectual Property Portfolio:

• Patent Strategy: Actively seeks to obtain and maintain patent protection for compositions comprising antibodies, classes of antibodies, methods of use, diagnostic methods, pharmaceutical compositions, combination therapies, and manufacturing methods. Owns three issued U.S. patents related to broadly neutralizing anti-coronavirus antibodies (adintrevimab, ADG10) and uses thereof, expected to expire in 2041. Owns pending patent families for adintrevimab formulations (expiring 2042), additional anti-coronavirus antibodies (expiring 2043), VYD222 (expiring 2043), VYD2311 (expiring 2045), and VBY329 (expiring 2046).
• Licensing Programs: Has exclusive options under the Adimab Collaboration Agreement to obtain licenses and assignments for commercializing selected products.
• IP Litigation: Not currently a party to any material legal proceedings as of December 31, 2025.
• Trade Secret Strategy: Relies on trade secret protection and confidentiality agreements for proprietary scientific, business, and technical information and know-how.

Technology Partnerships:

• Adimab, LLC: Long-standing partnership for antibody discovery, engineering, and optimization. Includes an Assignment and License Agreement (July 2020) for existing coronavirus antibodies, a Collaboration Agreement (May 2021) for new antibody discovery, and a Platform Transfer Agreement (September 2022) granting rights to practice certain elements of Adimab’s platform technology.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: William Duke, Jr. has served as Principal Executive Officer since May 2024 following the separation of the previous CEO. The company acknowledges that executive leadership transition periods can be difficult.

Board Composition: The Board of Directors has overall responsibility for risk oversight, with the Audit Committee overseeing cybersecurity risk management and strategy. Tamsin Berry, a member of the board, is a Limited Partner of Population Health Partners, L.P., a former service provider to the company.

Human Capital Strategy

Workforce Composition:

• Total Employees: 122 (as of February 1, 2026), all full-time.
• Geographic Distribution: Approximately 34% in Massachusetts, 9% in Connecticut, 7% in California, 7% in New Jersey, and 43% in various other states.
• Skill Mix: Approximately 16 employees hold Ph.D. or M.D. degrees; 35 employees are engaged in research and development activities.

Talent Management: Acquisition & Retention:

• Hiring Strategy: Focus on identifying, recruiting, retaining, incentivizing, and integrating employees, advisors, and consultants.
• Retention Metrics: Not explicitly detailed in the filing.
• Employee Value Proposition: Utilizes equity and cash incentive plans to attract, retain, and reward personnel.

Diversity & Development:

• Diversity Metrics: Not explicitly detailed in the filing.
• Development Programs: Not explicitly detailed in the filing.
• Culture & Engagement: Considers its relationship with employees to be strong. Operates as a hybrid company.

Environmental & Social Impact

Not explicitly detailed in the filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly detailed in the filing, but the company acknowledges that the commercial market for COVID-19 therapeutics may develop greater seasonality of demand.
• Economic Sensitivity: The company's business and operations could be adversely affected by unfavorable global economic conditions and geopolitical events.
• Industry Cycles: The success of the company's COVID-19 product candidates is subject to the unpredictable nature of the global health threat, which could change, dissipate, or stabilize, limiting demand.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: Subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies in the U.S., and comparable foreign authorities. Biologics are licensed under the PHS Act and regulated under the FDCA. Regulations govern testing, development, manufacturing, quality control, safety, purity, potency, efficacy, approval, labeling, packaging, storage, record keeping, distribution, marketing, sales, import, export, reporting, advertising, and promotional practices.
• International Compliance: Subject to varying regulatory requirements in other jurisdictions for clinical trials and commercial sales. European Union regulations include the Clinical Trials Regulation (CTR) and Marketing Authorization Application (MAA) procedures (centralized, mutual recognition, decentralized, national). The European Union's HTA Regulation became effective January 12, 2025, aiming to harmonize clinical benefit assessment. The United Kingdom's regulatory regime largely mirrors the European Union's, with a single marketing authorization covering the whole of the United Kingdom since January 1, 2025.

Trade & Export Controls:

• Export Restrictions: Experienced delays in clinical supply shipment due to Chinese government export approval procedures for COVID-19 products.
• Sanctions Compliance: Foreign CDMOs, including WuXi Biologics, may become subject to U.S. legislation (e.g., BIOSECURE Act), investigations, sanctions, or trade restrictions, which could impact costs, supply, and U.S. government contracting opportunities.

Legal Proceedings: As of December 31, 2025, the company was not a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for the years ended December 31, 2025 and 2024, due to a full valuation allowance against net deferred tax assets.
• Geographic Tax Planning: Not explicitly detailed in the filing.
• Tax Reform Impact:
  • NOL Carryforwards: U.S. federal NOL carryforwards of $485.8 million (indefinite carryforward, limited to 80% of taxable income). State NOL carryforwards of $286.9 million ($41.8 million indefinite, $245.1 million expiring from 2031).
  • R&D Tax Credits: U.S. federal R&D tax credit carryforwards of $24.8 million (expiring from 2040). State R&D tax credit carryforwards of $7.7 million (expiring from 2036).
  • Section 382 Limitations: Utilization of NOLs and tax credits may be subject to annual limitations due to potential "ownership changes" under Section 382 of the Internal Revenue Code.
  • Tax Act (2022): Elimination of the option to deduct R&D expenditures, now requiring amortization over five or fifteen years.
  • Pillar Two Framework: Monitoring the implementation of the Organisation for Economic Co-operation and Development's Pillar Two framework (15% global corporate minimum tax), not expected to have a material impact on the effective tax rate.

Insurance & Risk Transfer

Risk Management Framework: The company has established policies and processes for assessing, identifying, and managing risks from foreseeable cybersecurity threats and for detecting and responding to cybersecurity incidents, aligned with NIST Cybersecurity Framework principles. It maintains an Enterprise Risk Register to identify, prioritize, and track system risks, including cybersecurity risks.

Insurance Coverage:

• Cybersecurity Insurance: Maintains cybersecurity insurance, but coverage may not be sufficient to cover total losses or damages related to a cybersecurity incident.
• Product Liability Insurance: Maintains product liability insurance coverage, but it may not be adequate to cover all liabilities.
• Hazardous Waste Insurance: Does not carry specific biological or hazardous waste insurance coverage; property, casualty, and general liability policies exclude coverage for damages and fines from biological or hazardous waste exposure or contamination.
• Indemnification Agreements: Provides indemnification to vendors, lessors, CROs, CDMOs, business partners, and executive officers/directors, with maximum potential future payments often unlimited.